Giant Biogene Holding
Profile
Giant Biogene Holding Co., Ltd (HKEX: 2367; “the Company”) is an investment holding company whose subsidiaries primarily research, develop, manufacture and sell bioactive ingredient-based beauty and health products in China, using in-house synthetic biology to mass-produce recombinant collagen and rare ginsenosides. Core products include KOMFYMED professional skin treatment products (e.g., Collagen Stick 2.0) and COLLGENE collagen-based skincare plus Class III medical devices/dressings; it also develops rare ginsenosides functional foods. Founded/ancestry: operating entity Xi’an Giant Biogene traces back to 2000; the Company was incorporated in Cayman Islands on 28 July 2021. Headquarters/addresses reported: Xi’an, Shaanxi (Chang’An District, No. 1855 Xi’an) and a Hong Kong office at 19/F, Lee Garden One, 33 Hysan Ave, Causeway Bay. It is publicly listed on the Hong Kong Stock Exchange (2367); major shareholder shown: Juzi Holding ~54%. Employees: 2,201 full-time as of 31 Dec 2025; 2,319 as of 30 Jun 2026. Scale: 2025 revenue RMB 5,518.55 million; net profit RMB 1,914.72 million; patents granted/applied over 233 as of latest reporting. Distribution scale: products entered ~1,700 public hospitals, ~3,500 private hospitals/clinics, 130,000+ chain pharmacies, ~6,000 CS/KA stores; KOMFYMED opened 32 brand stores by end of the reporting period. Latest 2025–2026 developments: NMPA approvals in Oct 2025 and Jan 2026 for its Recombinant Type I α1 collagen products (Class III medical devices), and NMPA approvals in Jan and Jun 2026 for implant/filler products including a recombinant collagen-sodium hyaluronate composite solution implant and a cross-linked recombinant Type III collagen filler product. It was still active as of the 2026 filings and as of 30 Jun 2026 it reported 2,319 employees and ongoing commercialization preparation.
Sources#
- Industry
- Cosmetics
- Topics
- Hyaluronic acid, collagen & cosmetic bio-actives
- Role
- Distributor — “…as of latest reporting [7]. Distribution scale: products entered ~1,700 public hospitals, ~3,500 private hospi…”
Bio-solutions it supplies 1
What they offer
This company does not publish its products or services — we find out through an introduction.
News & status 6
- 2026-08 Latest status: The company shut down its SKIGIN nutricosmetics joint venture in August 2026 to refocus on medical aesthetics. ↗ ↗ ↗
- Status review: active — Closed one JV (SKIGIN, Aug 2026); core business operating.
- 2026-08-05 Giant Biogene Shuts Down Nutricosmetics Venture to Refocus on Medical AestheticsGiant Biogene is pivoting from consumer nutricosmetics to high-margin medical aesthetics, shuttering the SKIGIN venture but continuing its core R&D in recombinant collagen and expanding its regulated medical device and clinical channels for stronger …
- 2026-09-10 巨子生物人参皂苷CK获十佳原料
近... 来自巨子生物 - 微博GiantBio (巨子生物) is presenting its self-developed GiantBio-GSND CK ginseng saponin as a top cosmetic raw material, highlighting its multi-year focus on rare ginseng saponins, large-scale 100 kg production of five rare saponins, national and provincial …
- 2026-06-17 Giant Biogene Unit Gets Registration Certificate for Neck Wrinkle Injection | MarketScreener Hong KongGiant Biogene Holding Co., Ltd. (2367) is a Personal Products company whose stock recently rose to about 30.30 HKD, with a consensus rating of Buy from 17 analysts. The firm announced it received a registration certificate for a neck wrinkle injection, …
- 2026-06-17 GIANT BIOGENE(02367.HK): Cross-linked Recombinant Collagen Implant Obtains NMPA Medical Device Registration Certificate, World’s First Filler Indicated for Neck Wrinkle Correction | NewTimeSpaceGiant Biogene Holding (02367.HK) has obtained NMPA medical device registration for its Cross-linked Recombinant Collagen Implant, the world’s first cross-linked recombinant Type III collagen filler for neck wrinkle treatment, marking a milestone in its …
- 2026-08-18 Giant Biogene H1 Profit DropsGiant Biogene Holding Co., Ltd. reported weaker first-half 2026 results, with net profit attributable to equity shareholders down 20.5% to RMB 939.71 million and revenue dipping to RMB 2.92 billion from RMB 3.11 billion year-over-year. The company expects to …
- 2026-06-17 Shaanxi Giant Biotechnology Co., Ltd. Receives Medical Device Registration Certificate of the People's Republic of China Issued by China National Medical Products Administration | MarketScreener AustraliaGiant Biogene Holding Co., Ltd. announced that its subsidiary Shaanxi Giant Biotechnology Co., Ltd. received the PRC Medical Device Registration Certificate for a Cross-linked Recombinant Collagen Implant, making it the world’s first cross-linked recombinant …
Network: owners, partners, peers
Ownership & investors 1
| parent | Hillhouse Investment |
Similar companies
Jland Biotech · Aktin Chemicals · Laurus Bio · Nippi, Inc. · GF FERMENTECH Inc. / 지에프퍼멘텍 · CKD Bio Corporation · CJ CheilJedang · Zhejiang Xinmei Biotechnology Co. Ltd.
Identity & contacts
Contacts, people and legal identity are available to members.
Sign in as a member